Found 475 results in Expert Content

Catalent’s experts presented technical posters on advanced drug design, discovery, development, delivery, packaging and scale-up. Click here to download [Part 1] of the 2015 AAPS posters Click here to...

Catalent with deep scientific expertise has the broadest capabilies and advancved technologies for controlled and modified release products.

This eBook published by Pharmaceutical Technology provides an overview of the regulatory landscape related to elemental impurities testing, discusses the challenges of implementing ICH Q3D guidelines ...

You will learn about a pharmaceutical company who was interested in scaling-up a multi-particulate, modified-release product to a commercial scale using fluid bed bottom-spray (Wurster) coating.

Summary: Given the accelerated timelines associated with expedited programs, lipid-based drug formulations, encapsulated in softgel capsules, provide an attractive option for addressing the challenges...

From the top industry partner for development, launch and supply of new treatments, Catalent offers integrated solutions for pulmonary and nasal delivery with significant capacity in North America. Our in-house capabilities span clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and multi-dose nasal sprays

Lipid based drug delivery systems (LBDDS) are the most studied and understood bioavailability enhancing solutions

Summary: It is vital that drug products reach patients uncontaminated and unadulterated by their packaging. Extractables and leachables (E&L) are especially of concern for liquid injectable...

To be successful, new treatments require real-world outcomes for you, your stakeholders, and most importantly the patients.

The pharmaceutical industry has experienced a trend in the number of accelerated approval designations for drugs (e.g. orphan drugs, breakthrough therapies, accelerated approvals, and FDA priority reviews) being developed.